SGLT2 Inhibitors and Long-Term Outcomes After AKI
Empagliflozin could not show reduction in MAKE365 but showed potential benefits in reducing recurrent AKI.
Authors
- Weerachai Chaijamorn (ORCID: https://orcid.org/0000-0003-3781-5062)
- Veerapatr Nimkietkajorn
- Nuttha Lumlertgul (ORCID: https://orcid.org/0000-0003-1506-4253)
- Sadudee Peerapornratana
- Akarathep Leewongworasingh
- Khanitha Yimsangyad
- Nattachai Srisawat (ORCID: https://orcid.org/0000-0002-8544-8132)
- Anyarin Wannakittirat (ORCID: https://orcid.org/0009-0008-4815-0637)
- Nattira Sorose
- Peerapat Thanapongsathorn
Institutions
- Chulalongkorn University (TH)
- King Chulalongkorn Memorial Hospital (TH)
- Phitsanulok University (TH)
- Central Chest Institute of Thailand (TH)
- Buddhachinaraj Hospital (TH)
- The Royal College Of Anesthesiologists Of Thailand (TH)
- Naresuan University Hospital (TH)
- Office of the Royal Society
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1016/j.ekir.2025.103752
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chulalongkorn University